Markets:

Overview

News

Currencies

International

Treasuries

Bayer Ag ADR (OP:BAYRY)

11.91 -0.09 (-0.75%)

Streaming Delayed Price Updated: 2:03 PM EDT, Apr 14, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Bayer Ag ADR

< Previous 1 2 3 4 5 6 7 8 9 Next >

Regeneron Gains As New Data Favors Higher Dose Of Flagship Eye Disease Drug ↗

September 08, 2022

Via Benzinga

7 Stocks Under $15 to Buy and Hold Forever ↗

September 01, 2022

For patient investors who are willing to absorb potential turbulence, these are the stocks under $15 to buy for the long haul.

Via InvestorPlace

Bayer's Kidney Disease Drug Disappoints On Cutting Cardiovascular Death ↗

August 29, 2022

Via Benzinga

Bristol Myers Squibb, Bayer Stocks Hit The Deck On Blood Thinner Flops ↗

August 29, 2022

The companies hoped to reduce the risk of myriad complications for at-risk patients.

Via Investor's Business Daily

Bayer, Exscientia Part Ways On Artificial Intelligence Collaboration ↗

August 18, 2022

Via Benzinga

FDA Approves Expanded Use For Bayer's Prostate Cancer Drug ↗

August 08, 2022

Via Benzinga

Read Why Did HC Wainwright Cut Price Target On Atara Biotherapeutics ↗

May 23, 2022

Via Benzinga

Recap: Bayer Q4 Earnings ↗

March 01, 2022

Bayer (OTC:BAYRY) reported its Q4 earnings results on Tuesday, March 1, 2022 at 01:30 AM. Here's what investors need to know about the announcement. Earnings Bayer beat...

Via Benzinga

This Biotech Says Stem Cells May Be Key To Freeing 65 Million Americans From Chronic Back Pain, Painkiller Dependence ↗

July 27, 2022

BioRestorative Therapies Inc. (NASDAQ: BRTX), a stem cell-focused biotech, says it wants to shift the paradigm of how doctors treat chronic pain in hopes of giving patients an option that’s effective,...

Via Benzinga

Why Is Ginkgo Bioworks (DNA) Stock in the Spotlight Today? ↗

July 25, 2022

DNA stock is down even while Ginkgo Bioworks prepares to purchase a biotech business and a large research and development site.

Via InvestorPlace

Science Wednesday: 'Silent Spring' At 60; Preserved Baby Mammoth Found In Yukon; Filling Medical Imaging, Nursing Shortages ↗

June 29, 2022

(This marks the first installment of Benzinga’s new weekly series Science Wednesday, which provides an overview of news and milestones within the sciences.)

Via Benzinga

BWXT Medical, Bayer Ink Commercial Agreement For Actinium-225 Based Products ↗

June 27, 2022

Via Benzinga

SpringWorks Therapeutics Shares Jump On HC Wainwright Bullish Pitch ↗

June 13, 2022

HC Wainwright points out that investors are enthusiastic about SpringWorks Therapeutics Inc (NASDAQ: SWTX) nirogacestat clinical profile for desmoid tumors after the R&D day held last week.

Via Benzinga

7 Blue-Chip Stocks to Buy Now if You Have $250 to Spend ↗

June 08, 2022

These seven blue-chip stocks are trading at relative bargains and they can all be added to your portfolio for less than $250.

Via InvestorPlace

Pfizer To Quit GSK's Consumer Health JV Following Its Spin-Off ↗

June 01, 2022

Via Benzinga

Three Stocks To Buy In This Bear Market ↗

May 30, 2022

There’s a silver lining to the current bear market. It’s created great buying opportunities.

Via Talk Markets

The Daily Biotech Pulse: CDC Recommends COVID-19 Boosters For Kids 5-11, Foghorn's Blood Cancer Trial On Clinical Hold, Bayer Intends To Bow Out From CAR-T Therapy Pact With Atara ↗

May 20, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Bayer Intends To Bow Out From CAR-T Therapy Pact With Atara ↗

May 20, 2022

Via Benzinga

How Heart Drugs Could Pump $10 Billion Into Merck's Coffers ↗

May 19, 2022

As Keytruda's patent protection looms, will Merck be able to stanch the sales losses?

Via Investor's Business Daily

The Daily Biotech Pulse: Pfizer Acquires Migraine Drugmaker For $11B, Biogen Files For Second Alzheimer's Drug Approval, Longeveron CEO Leaves ↗

May 10, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

22nd Century Group Reports Q1 Net Sales Of $9M, Up 33% YoY, Net Loss Also Grows ↗

May 05, 2022

22nd Century Group, Inc. (NASDAQ: XXII) reported results for the first quarter ended March 31, 2022.. The company will host a live audio webcast on May 5, at 10:00 a.m. ET.

Via Benzinga

Investment Strategy Monthly Insights, April 2022 ↗

April 22, 2022

After four decades of low inflation, developed economies are grappling with an inflation spike.

Via Talk Markets

FDA Puts Blood Cancer Nods Under Scrutiny On Substantial Toxicity Profile Of PI3K Drugs ↗

April 21, 2022

The FDA aims to put the PI3K inhibitor drug class under a more stringent regulatory scope as the inhibitor has demonstrated substantial toxicity.

Via Benzinga

Merck Projects $10 Billion From Its Next Blockbuster Segment; Will It Measure Up? ↗

April 05, 2022

Merck shares hit a six-month high Tuesday on the bullish projection.

Via Investor's Business Daily

What Stocks Do Well During a Bear Market? 7 Picks for a Downturn ↗

March 16, 2022

These are the best bear market stocks to invest in now. T, BG and CL are some great picks for investors looking to weather the storm.

Via InvestorPlace

Eli Lilly To Suspend Sale Of 'Non-Essential' Medicines To Russia ↗

March 15, 2022

Eli Lilly And Co (NYSE: LLY) said it would continue to supply drugs to Russia for urgent medical conditions such as cancer and diabetes but will suspend sales of "non-essential medicines."

Via Benzinga

The Daily Biotech Pulse: Biogen, Eisai Amend Aduhelm Agreement; Anaptys Acne Drug Flunks Midstage Study; Merck, AstraZeneca Discontinue Prostate Cancer Trial ↗

March 15, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Exelixis Will Not Pursue Untreated Liver Cancer Indication For Cabometyx Combo Therapy ↗

March 15, 2022

Exelixis Inc (NASDAQ: EXEL) announced results from the final analysis of the second primary endpoint of overall survival (OS) from the phase 3 COSMIC-312 trial of Cabometyx (cabozantinib) plus...

Via Benzinga

Biotech Stocks Are Down And Out; Can These 2022 Trends Save Them? ↗

February 17, 2022

Can the formerly red-hot biotech segment return to its previous glory?

Via Investor's Business Daily

Aveo Says Tivozanib Patients Up To 5X More Likely To Experience Long-Term PFS Vs. Nexavar In Kidney Cancer ↗

February 15, 2022

Aveo Pharmaceuticals Inc (NASDAQ: AVEO) will present new long-term progression-free survival (PFS) data from the Phase 3 TIVO-3 study in kidney cancer at the 2022...

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.